Anyone familiar with the PIRS/AZN collaboration?
One of the reasons given on other forums for short sellers betting against BPMX is that "collaborations don't come until after a successful phase 3..." LMAO
In May, AstraZeneca (AZN) entered into a collaboration with Pieris for $45 million upfront and the possibility of an additional $2.1 BILLION more in milestone attainments plus royalties on sales.
Now PIRS is charged with taking their lead respiratory drug — PRS-060, an Anticalin against interleukin-4 receptor alpha — into a PHASE I (ONE!) asthma trial. Once they do that, they can score $12.5 million to add to the $45 million upfront they are getting in the pact...
PIRS has the right to grab co-development and co-commercialization rights on the lead program after Phase IIa, and then AZN has rights to develop four more of these respiratory Anticalins, with PIRS able to partner on two of these therapies...
The BPMX Anhydrous Hydrophilic Topical System is another unique & patented technology that Big Pharma lusts over. The chances of a BPMX collaboration with a major player are very strong IMO...
GLTL
